Island Pharmaceuticals (ASX: ILA) is significantly expanding its antiviral pipeline by collaborating with Burnet Institute to evaluate ISLA-101 and Galidesivir against the measles, chikungunya, and Ross River viruses.
This strategic partnership aims to expand the company's antiviral pipeline by leveraging existing datasets and scientific expertise.
The work at Burnet Institute will be led by Dr Johanna Fraser.
Critically, the collaboration is supported by an NHMRC grant of over $780,000 AUD over three years specifically allocated to support the translational and clinical work for ISLA-101.
The expansion of the pipeline aligns with national stockpile, biodefense, and public health preparedness frameworks, highlighting the potential broader impact of Island Pharmaceuticals' antiviral programs.
Galidesivir Continues US Biodefense Push
This new collaboration builds upon Island Pharmaceuticals' ongoing efforts in the biodefense space.
The company entered a three-year Cooperative Research and Development Agreement (CRADA) on 3 March 2026.
This CRADA is with USAMRIID and The Geneva Foundation, focused on advancing Galidesivir for Marburg Virus Disease (MVD) under the FDA Animal Rule.
The collaboration includes designing and conducting non-human primate (NHP) studies, crucial steps towards New Drug Application (NDA) readiness for Galidesivir.
To fund these critical programs, Island Pharmaceuticals successfully completed a $9 million private placement dedicated to fully supporting the two-stage Animal Rule development of Galidesivir.
Pipeline Expansion and De-Risking
The collaboration with Burnet Institute represents a strategic expansion without new molecule acquisition or material capital outlay for Island Pharmaceuticals.
Instead, it focuses on maximising the value of its existing assets.
The external funding secured through the NHMRC grant is designed to de-risk the ISLA-101 program, providing financial support for its translational and clinical development and strengthening intellectual property.
This approach underscores Island Pharmaceuticals' strategy to leverage its current portfolio for broad antiviral applications, addressing multiple high-priority pathogens efficiently.
Investor Risks and Outlook
Investors considering Island Pharmaceuticals should be aware of several key risks inherent in pharmaceutical development.
These include the uncertainty in translating preclinical data to successful clinical milestones, the complexities of regulatory approvals, and the timelines associated with drug development.
While the company has made progress in securing funding and partnerships, the effectiveness of these collaborations and the ultimate success of regulatory pathways are ongoing considerations.
Island Pharmaceuticals hopes this latest initiative will complement its ongoing efforts to advance Galidesivir within the US biodefense framework, further de-risk development and broaden market opportunities.
